Retatrutide produces more weight loss than tirzepatide based on available clinical data. Retatrutide trial participants lost an average of 28.7% of body weight at the highest dose, compared to 22.5% with tirzepatide at its highest approved dose (15mg). That is a meaningful difference of over 6 percentage points, which translates to roughly 15 additional pounds of weight loss for a typical patient. Both drugs are manufactured by Eli Lilly, and retatrutide is widely seen as the company's next-generation successor to tirzepatide.

Before diving into the details, one important caveat: these numbers come from separate clinical trials with different patient populations, trial durations, and protocols. A direct head-to-head comparison has not been conducted. That said, the size of the difference makes it very likely that retatrutide would outperform tirzepatide even in a controlled direct comparison.

The Numbers Side by Side

Here is how the weight loss data compares across the key clinical trials:

Retatrutide Phase 2 (48 weeks):

• 4mg dose: approximately 17.0% body weight loss
• 8mg dose: approximately 24.3% body weight loss
• 12mg dose: 28.7% body weight loss (and the curve had not yet plateaued)

Tirzepatide SURMOUNT-1 (72 weeks):

• 5mg dose: approximately 15.0% body weight loss
• 10mg dose: approximately 19.5% body weight loss
• 15mg dose: approximately 22.5% body weight loss

Several details make this comparison even more striking. First, retatrutide achieved its results in a shorter timeframe. The Phase 2 trial ran for 48 weeks, while tirzepatide's SURMOUNT-1 trial ran for 72 weeks. In other words, retatrutide produced more weight loss in less time. Second, the retatrutide weight loss curve was still trending downward at 48 weeks, suggesting that with a longer treatment period (like the 72-week trials in the Phase 3 TRIUMPH program), the final numbers could be even higher.

If retatrutide's trajectory continues through 72 weeks at the same rate, some researchers have estimated the total weight loss could approach 30-32% of body weight. Phase 3 data will confirm or adjust this projection.

Why Retatrutide Outperforms Tirzepatide

The difference in results comes down to the drugs' mechanisms. Tirzepatide is a dual agonist, targeting GLP-1 and GIP receptors. Retatrutide is a triple agonist, targeting GLP-1, GIP, and glucagon receptors. Both drugs share the same first two targets, so the performance difference is largely attributable to retatrutide's additional glucagon receptor activity.

Glucagon receptor activation contributes to weight loss in ways that GLP-1 and GIP do not:

• Increased metabolic rate: Glucagon signals the body to burn more energy at rest. While tirzepatide works primarily by reducing how much you eat, retatrutide also increases how much you burn. This dual approach creates a wider caloric deficit.
• Enhanced fat breakdown: Glucagon promotes lipolysis, the process of breaking down stored fat for energy. This means retatrutide may be particularly effective at targeting stored body fat rather than lean tissue.
• Liver fat reduction: Glucagon promotes the clearance of fat from the liver. Phase 2 data showed significant liver fat reductions in retatrutide participants, which is both a weight loss mechanism and an independent health benefit.

In simple terms, tirzepatide makes you eat less. Retatrutide makes you eat less and burn more. The addition of that second mechanism is what drives the superior weight loss numbers.

Side Effect Comparison

Both drugs share a similar gastrointestinal side effect profile. Nausea, diarrhea, vomiting, and constipation are common with both medications, particularly during dose escalation. However, there are some differences worth noting.

Tirzepatide's side effect profile is well-established from its Phase 3 trials and real-world use since 2022. GI side effects are reported by roughly 40-50% of patients at the highest dose, but they are generally manageable and tend to improve over time. Serious adverse events are rare, and the drug's overall tolerability has been considered acceptable by both patients and prescribers.

Retatrutide's Phase 2 data showed GI side effect rates that were broadly comparable to tirzepatide, with nausea being the most frequently reported symptom at approximately 45% on the highest dose. The addition of glucagon activity does not appear to dramatically worsen the GI side effect burden, which is encouraging.

One area where the drugs differ is the potential for unique side effects related to glucagon activation. As discussed, glucagon raises blood sugar, which could be a concern for some patients. In retatrutide trials, this effect was offset by the GLP-1 and GIP components, and overall glycemic control improved. Still, longer-term monitoring will be important, particularly for patients with prediabetes or insulin resistance.

Tirzepatide has the advantage of a more extensive safety database. Millions of prescriptions have been filled since its launch, providing far more real-world data than retatrutide's clinical trial database of a few thousand participants. For risk-averse patients, this established track record is a meaningful point in tirzepatide's favor.

Availability Timeline

This is perhaps the most practical difference between the two drugs right now. Tirzepatide is FDA-approved and available today, marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes. You can get a prescription from your doctor and fill it at a pharmacy (supply permitting) right now.

Retatrutide is still in Phase 3 clinical trials and is not expected to receive FDA approval until late 2027 or early 2028. For patients who need treatment now, tirzepatide is the clear choice simply because it exists as an option.

For patients who are earlier in their weight loss journey or who are already on tirzepatide, the question becomes whether to wait for retatrutide or switch once it becomes available. This is a decision that should be made with a healthcare provider based on individual circumstances, including how well tirzepatide is working, tolerability, and treatment goals.

Cost Considerations

Tirzepatide (Zepbound) currently has a list price of approximately $1,060 per month. Retatrutide's pricing has not been announced, but analysts expect it to cost between $1,000 and $1,500 per month. If retatrutide launches at a premium over Zepbound, the cost difference will be another factor in the decision between the two drugs.

Insurance coverage adds another layer of complexity. Tirzepatide has had time to negotiate formulary positions with major insurers. Retatrutide will need to go through this same process after launch, which means coverage may be limited initially. Some insurers may require patients to try and fail on tirzepatide before approving coverage for the more expensive retatrutide, a practice known as step therapy.

Which Should You Choose?

If you need a weight loss medication today, tirzepatide is the most effective FDA-approved option available. It produces an average of 22.5% body weight loss at the highest dose, which is a remarkable result by any historical standard. For many patients, this level of weight loss is life-changing and sufficient to resolve or significantly improve obesity-related health conditions.

If you are looking toward the future and are willing to wait, retatrutide appears poised to set a new bar. The additional 6+ percentage points of weight loss over tirzepatide could be particularly meaningful for patients with higher BMIs who need to lose a larger proportion of their body weight to reach health targets.

It is also worth considering that starting on tirzepatide now does not prevent you from switching to retatrutide later. Many patients may benefit from beginning treatment with an available drug, achieving significant initial weight loss, and then evaluating whether transitioning to retatrutide makes sense once it reaches the market. There is no clinical reason why a switch would not be feasible, though the specific protocols for transitioning between these medications will need to be established.

The bottom line is that both drugs represent remarkable advances in obesity treatment. Tirzepatide is available and proven. Retatrutide promises to be even better but requires patience. Working with a knowledgeable prescriber to navigate these options based on your individual health profile, goals, and timeline is the smartest approach.